BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome.
ConditionTakotsubo Syndrome
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorVastra Gotaland Region
About this trial
The aim of this study is to document an optimized pharmacologic treatment for patients with Takotsubo Syndrome. There is currently no published documentation in a large number of patients. The study is a Randomized Registry Clinical Trial and in total 1000 patients registered in SWEDEHEART will be included.
Eligibility criteria
Qualifiers
Age ≥ 18 years.
A clinical diagnosis of TS (see definition 2.1), including an ejection fraction (EF) ˂ 50 % at baseline
Written informed consent obtained
Disqualifiers
Previous randomization in the trial
Any concomitant condition resulting in a life expectancy of less than one month
Previously diagnosed left ventricular ejection fraction <50%
Known cardiomyopathy (except previous Takotsubo syndrome)
Trial design
Treatments tested in this trial
- Adenosine
- Dipyridamole 200 mg
- Apixaban 5 mg Oral Tablet
- Care as recommended by the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology for takotsubo syndrome
Treatment groups
1,000 Participants
are divided into 4 treatment groupsSponsors and collaborators
Vastra Gotaland Region
Lead sponsor
Göteborg University
Collaborator
Source ClinicalTrials.gov